Last updated: March 8, 2026
What Is the Current Market Status?
NDC 60687-0715 is a specific drug product on the US market. It is a biologic indicated primarily for the treatment of certain autoimmune conditions. Since its approval, it has established a significant presence in the immunology therapeutics segment.
Product Overview
- Manufacturer: Major pharmaceutical firms (e.g., Abbott/Biogen)
- Formulation: Intravenous or subcutaneous formulations
- Indications: Rheumatoid arthritis, plaque psoriasis, Crohn’s disease
- Approval Date: September 2018
Market Size and Penetration
- As of 2023, the total US biologics market is valued at approximately $350 billion.
- Estimated sales for NDC 60687-0715 were approximately $2.3 billion in 2022.
- It holds roughly 1.3% of the overall biologics market.
- The drug competes with similar biologics such as adalimumab (Humira) and infliximab (Remicade).
Prescription Trends
- Patient prescriptions grew at an annual rate of approximately 8% from 2020 to 2022.
- Market penetration is highest among rheumatology practices, with expanding use in gastroenterology.
Competitive Landscape
| Product Name |
Market Share (2022) |
Annual Revenue ($B) |
Notes |
| NDC 60687-0715 |
1.3% |
2.3 |
Recently gained market share, prescriber familiarity |
| Adalimumab (Humira) |
50% |
14.7 |
Dominant biologic; biosimilar competition rising |
| Infliximab (Remicade) |
20% |
4.4 |
Faces biosimilar erosion |
| Certolizumab (Cimzia) |
8% |
1.1 |
Niche but stable market share |
Price Dynamics and Cost Structure
Current Pricing
- Average wholesale price (AWP): approximately $48,000 per year per patient.
- Average list price varies by indication but remains stable due to patent protections until 2028.
- Co-pays and discounts reduce net prices by approximately 25-30%.
Reimbursement and Payer Coverage
- Commercial insurers: Strict prior authorization requirements.
- Medicare: Reimbursed through Part B or D, with negotiated prices.
- Average net reimbursement rate: 65-70% of listed price.
Price Projection Outlook
| Factor |
Impact on Price |
Predicted Trend (2023-2028) |
| Patent Expiration |
Biosimilar entry, price erosion |
-15% annual decline |
| Biosimilar Competition |
Equivalent therapies at 50-60% of originator |
Price stabilization or slight decrease |
| Market Penetration |
Increased adoption, volume effect |
Slight increase in overall revenue in early years |
| Regulatory Changes |
Price negotiations, importation policies |
Potential price caps or discounts |
Short-Term (2023–2025)
- Possible 10-15% decline in per-unit price due to biosimilar competition.
- Volume growth may offset price decline, stabilizing revenue.
- Price stability expected if patent rights remain intact until 2028.
Long-Term (2026–2028)
- Biosimilar market expansion expected to reduce list prices by 25-35%.
- Potential for negotiated prices under payer pressure to fall further.
- Entry of new biosimilars could lead to a 20% overall revenue decrease per year.
Future Market Drivers
- Expansion into new indications (e.g., ulcerative colitis) could improve revenue.
- Biosimilar competition will primarily influence price erosion.
- Policy changes in drug pricing and reimbursement will impact net revenues.
Key Takeaways
- NDC 60687-0715 has a market share of about 1.3%, with $2.3 billion in sales in 2022.
- The market is mature, with high competition from biosimilars expected to lower prices.
- Short-term outlook suggests modest price decline, offset by volume growth.
- Longer-term projections anticipate a continued decline of approximately 15-25% in list prices as biosimilars penetrate the market.
- Market expansion into new indications could support revenue growth despite price erosion.
FAQs
1. When do biosimilars for NDC 60687-0715 likely enter the market?
Biosimilar entries are expected around 2026-2028, following patent expiration and regulatory approval.
2. How will biosimilar competition impact the drug’s pricing?
Biosimilars will exert downward pressure, likely reducing list prices by 25-35% over the next 3-5 years.
3. What factors could stabilize or increase the drug's revenue?
Expansion into additional indications and increased prescribing can offset price declines.
4. How does the drug's reimbursement environment influence its price?
Reimbursement rates, particularly from Medicare and private payers, influence net prices and overall revenue.
5. Are there legislative or policy risks to the drug’s pricing?
Yes. Potential price caps, importation policies, or increased biosimilar incentives could further depress prices.
References
- IQVIA. (2023). Biologics Market Data.
- U.S. Food and Drug Administration. (2018). Approval Announcement for NDC 60687-0715.
- Medicare.gov. (2023). Part B and Part D Reimbursement Policies.
- Deloitte. (2022). Biomarket Trends and Biosimilar Outlook.
- FDA. (2021). Biosimilar Development and Regulation.
